ES2995959T3 - Methods for the detection and treatment of lung cancer - Google Patents
Methods for the detection and treatment of lung cancer Download PDFInfo
- Publication number
- ES2995959T3 ES2995959T3 ES18752036T ES18752036T ES2995959T3 ES 2995959 T3 ES2995959 T3 ES 2995959T3 ES 18752036 T ES18752036 T ES 18752036T ES 18752036 T ES18752036 T ES 18752036T ES 2995959 T3 ES2995959 T3 ES 2995959T3
- Authority
- ES
- Spain
- Prior art keywords
- lung cancer
- sftpb
- pro
- cea
- cyfra21
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
- G16B5/20—Probabilistic models
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biophysics (AREA)
- Medical Informatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Evolutionary Biology (AREA)
- Theoretical Computer Science (AREA)
- Physiology (AREA)
- Probability & Statistics with Applications (AREA)
- Databases & Information Systems (AREA)
- Evolutionary Computation (AREA)
- Bioethics (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Data Mining & Analysis (AREA)
- Signal Processing (AREA)
- Epidemiology (AREA)
- Artificial Intelligence (AREA)
- Public Health (AREA)
- Software Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762456731P | 2017-02-09 | 2017-02-09 | |
| PCT/US2018/017704 WO2018148600A1 (en) | 2017-02-09 | 2018-02-09 | Methods for the detection and treatment of lung cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2995959T3 true ES2995959T3 (en) | 2025-02-11 |
Family
ID=63107741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES18752036T Active ES2995959T3 (en) | 2017-02-09 | 2018-02-09 | Methods for the detection and treatment of lung cancer |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US12504430B2 (https=) |
| EP (2) | EP4528741A3 (https=) |
| JP (1) | JP7311417B2 (https=) |
| KR (2) | KR102827354B1 (https=) |
| CN (2) | CN110291397A (https=) |
| CA (1) | CA3053116A1 (https=) |
| ES (1) | ES2995959T3 (https=) |
| WO (1) | WO2018148600A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110291397A (zh) | 2017-02-09 | 2019-09-27 | 得克萨斯大学体系董事会 | 肺癌的检测和治疗方法 |
| WO2021016711A1 (en) * | 2019-07-29 | 2021-02-04 | Biomark Cancer Systems Inc. | Method of discriminating lung cancer patients |
| CA3165068A1 (en) | 2020-01-30 | 2021-08-05 | John E. Blume | Lung biomarkers and methods of use thereof |
| EP4143578B1 (en) * | 2020-04-28 | 2024-06-05 | Luxembourg Institute of Health (LIH) | Biomarkers for detection of lung cancer |
| WO2022051753A1 (en) * | 2020-09-01 | 2022-03-10 | Oncodea Corporation | Predictive diagnostic test for early detection and monitoring of diseases |
| CN112147099A (zh) * | 2020-09-22 | 2020-12-29 | 范庆坤 | 一种m蛋白紫外分光检测法 |
| KR20230080442A (ko) * | 2020-10-02 | 2023-06-07 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 폐암의 검출 및 치료를 위한 방법 |
| EP4237090B1 (en) * | 2020-10-29 | 2026-02-18 | Board of Regents, The University of Texas System | Methods for the detection and treatment of ovarian cancer |
| AU2021409465A1 (en) | 2020-12-21 | 2023-08-03 | Freenome Holdings, Inc. | Markers for the early detection of colon cell proliferative disorders |
| US12334190B2 (en) | 2021-03-31 | 2025-06-17 | PrognomIQ, Inc. | Multi-omic assessment using proteins and nucleic acids |
| GB2607436A (en) * | 2021-03-31 | 2022-12-07 | Prognomiq Inc | Multi-omic assessment |
| CN113267587B (zh) * | 2021-05-27 | 2023-11-10 | 杭州广科安德生物科技有限公司 | 测定pro-SFTPB标准物质含量的特征肽段及方法 |
| US12387508B2 (en) | 2021-09-10 | 2025-08-12 | PrognomIQ, Inc. | Direct classification of raw biomolecule measurement data |
| US12007397B2 (en) | 2021-09-13 | 2024-06-11 | PrognomIQ, Inc. | Enhanced detection and quantitation of biomolecules |
| WO2023209218A1 (en) * | 2022-04-28 | 2023-11-02 | Janssen Pharmaceutica Nv | Metabolite predictors for lung cancer |
| EP4357782A1 (en) * | 2022-10-18 | 2024-04-24 | MU Bioteknik Aktiebolag | Protein biomarker panel for the diagnosis of colorectal cancer |
| CN115575636B (zh) * | 2022-11-22 | 2023-04-04 | 杭州广科安德生物科技有限公司 | 一种用于肺癌检测的生物标志物及其系统 |
| CN116593702B (zh) * | 2023-05-11 | 2024-04-05 | 杭州广科安德生物科技有限公司 | 一种肺癌的生物标志物以及诊断系统 |
| WO2025064345A2 (en) * | 2023-09-22 | 2025-03-27 | Board Of Regents, The University Of Texas System | Methods for the detection and treatment of lung cancer |
| CN118983078B (zh) * | 2024-08-15 | 2025-03-25 | 立本医疗器械(成都)有限公司 | 基于ptr-tof-ms的肺癌筛查模型构建方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1969363B1 (en) * | 2005-12-22 | 2016-11-30 | Abbott Molecular Inc. | Methods and marker combinations for screening for predisposition to lung cancer |
| US9347945B2 (en) | 2005-12-22 | 2016-05-24 | Abbott Molecular Inc. | Methods and marker combinations for screening for predisposition to lung cancer |
| US20080133141A1 (en) * | 2005-12-22 | 2008-06-05 | Frost Stephen J | Weighted Scoring Methods and Use Thereof in Screening |
| CA2681667A1 (en) * | 2007-05-18 | 2008-11-27 | Duke University | Serum biomarkers for the early detection of lung cancer |
| WO2012006632A2 (en) | 2010-07-09 | 2012-01-12 | Somalogic, Inc. | Lung cancer biomarkers and uses thereof |
| EP2567232A1 (en) * | 2010-05-07 | 2013-03-13 | AbbVie Inc. | Methods for predicting sensitivity to treatment with a targeted tyrosine kinase inhibitor |
| US20120087860A1 (en) * | 2010-05-24 | 2012-04-12 | Marek Malecki | Methods for in vivo cancer detection, diagnosis and therapy using multidomain biotags |
| WO2011150974A1 (en) | 2010-06-03 | 2011-12-08 | Porto Conte Ricerche S.R.L. | Biomarkers for lung neuroendocrine tumors |
| CN102321760A (zh) * | 2011-08-26 | 2012-01-18 | 泸州医学院附属医院 | 一种非小细胞肺癌标志物及应用 |
| CA2799163C (en) * | 2011-12-18 | 2025-01-07 | 20/20 Genesystems, Inc. | Methods and algorithms for aiding in the detection of cancer |
| WO2013154998A1 (en) | 2012-04-09 | 2013-10-17 | Duke University | Serum biomarkers and pulmonary nodule size for the early detection of lung cancer |
| US20140271453A1 (en) * | 2013-03-14 | 2014-09-18 | Abbott Laboratories | Methods for the early detection of lung cancer |
| US9753037B2 (en) | 2013-03-15 | 2017-09-05 | Rush University Medical Center | Biomarker panel for detecting lung cancer |
| US20150072890A1 (en) * | 2013-09-11 | 2015-03-12 | 20/20 Gene Systems, Inc. | Methods and compositions for aiding in the detection of lung cancer |
| US20160060329A1 (en) * | 2014-07-28 | 2016-03-03 | Donald SIN | Compositions and methods for the diagnosis and prognosis of lung cancer |
| CA3198282A1 (en) * | 2015-06-26 | 2016-12-29 | Biomark Cancer Systems Inc. | Method of detecting lung cancer |
| EP3427051B1 (en) | 2016-03-08 | 2021-06-16 | Magarray, Inc. | Protein and autoantibody biomarkers for the diagnosis and treatment of lung cancer |
| CN105717146B (zh) * | 2016-03-29 | 2018-11-09 | 复旦大学附属中山医院 | 一种基于ct影像及生物标志物谱针对中国城市人口高危人群的肺癌风险预测试剂盒 |
| CN109478231A (zh) | 2016-04-01 | 2019-03-15 | 20/20基因系统股份有限公司 | 帮助区别良性和恶性放射线照相明显肺结节的方法和组合物 |
| EP3361256A1 (en) | 2017-02-08 | 2018-08-15 | Fundación para la Investigación Médica Aplicada | In vitro method for the diagnosis of lung cancer |
| CN110291397A (zh) | 2017-02-09 | 2019-09-27 | 得克萨斯大学体系董事会 | 肺癌的检测和治疗方法 |
| IL319255A (en) | 2017-08-07 | 2025-04-01 | Univ Johns Hopkins | Methods and materials for cancer assessment and treatment |
| KR20230080442A (ko) | 2020-10-02 | 2023-06-07 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 폐암의 검출 및 치료를 위한 방법 |
| WO2024107923A1 (en) | 2022-11-17 | 2024-05-23 | Board Of Regents, The University Of Texas System | Methods for the detection and treatment of lung cancer |
| TR2022022101A2 (tr) | 2022-12-31 | 2023-04-24 | Atatuerk Ueniversitesi Fikri Muelkiyet Haklari Koordinatoerluegue Doener Sermaye Isletmesi | Nemlendi̇ri̇ci̇ modelaj örtüsü |
| EP4721103A2 (en) | 2023-05-31 | 2026-04-08 | Board of Regents, The University of Texas System | Methods for the detection and treatment of lung cancer |
| WO2025064345A2 (en) | 2023-09-22 | 2025-03-27 | Board Of Regents, The University Of Texas System | Methods for the detection and treatment of lung cancer |
-
2018
- 2018-02-09 CN CN201880010925.0A patent/CN110291397A/zh active Pending
- 2018-02-09 CA CA3053116A patent/CA3053116A1/en active Pending
- 2018-02-09 EP EP24204031.9A patent/EP4528741A3/en not_active Withdrawn
- 2018-02-09 EP EP18752036.6A patent/EP3580560B1/en active Active
- 2018-02-09 KR KR1020247002923A patent/KR102827354B1/ko active Active
- 2018-02-09 KR KR1020197026040A patent/KR102630885B1/ko active Active
- 2018-02-09 ES ES18752036T patent/ES2995959T3/es active Active
- 2018-02-09 CN CN202311117176.0A patent/CN117368475A/zh active Pending
- 2018-02-09 US US16/484,177 patent/US12504430B2/en active Active
- 2018-02-09 WO PCT/US2018/017704 patent/WO2018148600A1/en not_active Ceased
- 2018-02-09 JP JP2019542716A patent/JP7311417B2/ja active Active
-
2023
- 2023-03-28 US US18/191,506 patent/US12405274B2/en active Active
-
2025
- 2025-11-10 US US19/384,269 patent/US20260063638A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3580560A1 (en) | 2019-12-18 |
| CN117368475A (zh) | 2024-01-09 |
| WO2018148600A1 (en) | 2018-08-16 |
| EP4528741A3 (en) | 2025-04-09 |
| CA3053116A1 (en) | 2018-08-16 |
| KR20240015172A (ko) | 2024-02-02 |
| US12504430B2 (en) | 2025-12-23 |
| CN110291397A (zh) | 2019-09-27 |
| EP4528741A2 (en) | 2025-03-26 |
| JP7311417B2 (ja) | 2023-07-19 |
| US20200025766A1 (en) | 2020-01-23 |
| KR102630885B1 (ko) | 2024-01-29 |
| KR20190116368A (ko) | 2019-10-14 |
| US20260063638A1 (en) | 2026-03-05 |
| US20230314436A1 (en) | 2023-10-05 |
| EP3580560A4 (en) | 2020-12-09 |
| JP2020510816A (ja) | 2020-04-09 |
| KR102827354B1 (ko) | 2025-06-30 |
| EP3580560B1 (en) | 2024-10-02 |
| US12405274B2 (en) | 2025-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2995959T3 (en) | Methods for the detection and treatment of lung cancer | |
| Hollevoet et al. | Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis | |
| Rho et al. | Protein and glycomic plasma markers for early detection of adenoma and colon cancer | |
| Filella et al. | Clinical usefulness of circulating tumor markers | |
| Haab et al. | Definitive characterization of CA 19-9 in resectable pancreatic cancer using a reference set of serum and plasma specimens | |
| Amonkar et al. | Development and preliminary evaluation of a multivariate index assay for ovarian cancer | |
| Giessen et al. | Evaluation of preoperative serum markers for individual patient prognosis in stage I–III rectal cancer | |
| Greillier et al. | Biomarkers for malignant pleural mesothelioma: current status | |
| Hsu et al. | Serum markers of CYFRA 21-1 and C-reactive proteins in oral squamous cell carcinoma | |
| Moore et al. | Current clinical use of biomarkers for epithelial ovarian cancer | |
| van Veenendaal et al. | The Clinical Utility of Neuron-Specific Enolase (NSE) Serum Levels as a Biomarker for Merkel Cell Carcinoma (MCC) LM Veenendaal et al. | |
| Topuz et al. | Circulating calprotectin as a biomarker of laryngeal carcinoma | |
| Di Noia et al. | Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory “FoRECATT” study | |
| JP2021144052A (ja) | マーカー、ヒト精巣上体タンパク質４（ｈｅ４）に基づく肺腺癌の再発を検出する方法および関連する使用 | |
| Nasir Kansestani et al. | Comparison of faecal protein biomarkers' diagnostic accuracy for colorectal advanced neoplasms: a systematic review and meta-analysis | |
| Wang et al. | The role of autoantibody detection in the diagnosis and staging of lung cancer | |
| WO2024107923A1 (en) | Methods for the detection and treatment of lung cancer | |
| Liu et al. | Albumin‐to‐alkaline phosphatase ratio: A novel prognostic index for patients with driver mutation‐negative advanced non‐small cell lung cancer | |
| Jannawan et al. | High level of serum coiled-coil domain containing 25 (CCDC25) as a diagnostic marker for cholangiocarcinoma but not for other cancers | |
| KR20260030760A (ko) | 폐암의 검출 및 치료 방법 | |
| HK40105704A (zh) | 肺癌的检测和治疗方法 | |
| Mayasari et al. | Correlation of CD 133 biomarker with outcomes and therapy response in advanced-stage non-small cell lung carcinoma | |
| Mallikarjuna et al. | Seven blood biomarkers are associated with TGF-β and VHL-HIF signaling in patients with clear cell renal cell carcinoma | |
| CN121753110A (zh) | 肺癌检测方法 | |
| CN116762135A (zh) | 生物标志物在具有稳定疾病的非小细胞肺癌患者中的预后价值 |